Abstract
Clear cell renal cell carcinoma (ccRCC) is the most common subtype among renal cancer whose prognostic is affected by the tumor progression associated with complex gene interactions. However, there is currently no available molecular markers associated with ccRCC progression and used or clinical application. In our study, microarray data of 101 ccRCC samples and 95 normal kidney samples were analyzed and 2,425 differentially expressed genes (DEGs) were screened. Weighted gene co-expression network analysis (WGCNA) was then conducted and 11 co-expressed gene modules were identified. Module preservation analysis revealed that two modules (red and black) were found to be most stable. In addition, Pearson's correlation analysis identified the module most relevant to pathological stage(patho-module) (r = 0.44, p = 3e-07). Functional enrichment analysis showed that biological processes of the patho-module focused on cell cycle and cell division related biological process and pathway. In addition, 29 network hub genes highly related to ccRCC progression were identified from the stage module. These 29 hub genes were subsequently validated using 2 other independent datasets including GSE53757 (n = 72) and TCGA (n = 530), and the results indicated that all hub genes were significantly positive correlated with the 4 stages of ccRCC progression. Kaplan-Meier survival curve showed that patients with higher expression of each hub gene had significantly lower overall survival rate and disease-free survival rate, indicating that all hub genes could act as prognosis and recurrence/progression biomarkers of ccRCC. In summary, we identified 29 molecular markers correlated with different pathological stages of ccRCC. They may have important clinical implications for improving risk stratification, therapeutic decision and prognosis prediction in ccRCC patients.
Highlights
Renal carcinoma is a common malignancy of the urinary system and accounts for 2–3% of adult malignancies (Siegel et al, 2017)
CcRCC is the most common subtype among renal cancer whose prognostic is affected by the tumor progression associated with complex gene interactions
Exploring molecular markers of Clear cell renal cell carcinoma (ccRCC) is important for the diagnosis and treatment of patients with ccRCC
Summary
Renal carcinoma is a common malignancy of the urinary system and accounts for 2–3% of adult malignancies (Siegel et al, 2017). Surgery treatment is effective for localized RCC, once the RCC becomes metastatic the survival rate of patients will drop sharply. The standard treatment for localized RCC is surgery including radical or partial nephrectomy due to its insensitive to radiotherapy and chemotherapy (Motzer et al, 1996). For metastatic RCC, immunotherapy with interleukin-2 (IL-2) and interferon (IFN) was once the standard treatment, but it had limited curative effects and strong side effects (Negrier et al, 1998). Targeted therapies including sorafenib (Hutson et al, 2010) and sunitinib (Motzer et al, 2006) were approved for metastatic RCC in 2005 and 2006 respectively, with better effects and fewer side effects compared with immunotherapy. More effective diagnosis biomarkers and therapeutic targets are in urgent need
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
